Longeveron Inc. CEO Wa'el Hashad to Present at Biotech Showcase 2025 on January 14
Longeveron Inc. CEO Wa'el Hashad to Present at Biotech Showcase 2025 on January 14
Longeveron will present on January 14, 2025, from 4:00 to 4:30 p.m. PT.Longeveron Inc. CEO Wa'el Hashad will present at Biotech Showcase on January 14, 2025, discussing regenerative medicine developments.
Longeveron Inc. 首席执行官 Wa'el Hashad 将于2025年1月14日在生物技术展示会上发表演讲，讨论再生医学的发展。
Quiver AI Summary
Quiver AI 概要
Longeveron Inc., a clinical stage biotechnology company focused on regenerative medicine, announced that CEO Wa'el Hashad will present at the Biotech Showcase on January 14, 2025. The presentation will highlight the company's efforts in developing cellular therapies for serious and chronic aging-related conditions, specifically discussing their lead product, Lomecel-B, which is derived from young, healthy adult donors' bone marrow. Lomecel-B has potential applications in multiple areas, including hypoplastic left heart syndrome, Alzheimer's disease, and aging-related frailty, and has received several FDA designations. The presentation will be accessible via webcast on the company's website, with a replay available afterward.
Longeveron Inc.是一家专注于再生医学的临床阶段生物技术公司，宣布首席执行官 Wa'el Hashad 将于2025年1月14日在生物技术展示会上发表演讲。演讲将重点介绍该公司在开发用于严重和慢性与年龄相关疾病的电芯疗法方面的努力，特别讨论他们的主要产品 Lomecel-b，该产品源自年轻、健康成年捐赠者的骨髓。Lomecel-b 在多个领域具有潜在应用，包括左心发育不良综合征、阿尔茨海默病和与年龄相关的虚弱，并已获得多个 FDA 认证。演讲将在公司网站上通过网络直播，可以在之后观看回放。
Potential Positives
潜在的积极因素
- Wa'el Hashad, the CEO, is scheduled to present at Biotech Showcase, indicating active engagement with the biotech community and potential investor interest.
- The company's lead investigational product, Lomecel-B, has received multiple important FDA designations, showcasing regulatory recognition and support for its development in critical areas.
- Longeveron's focus on addressing unmet medical needs in significant conditions such as Alzheimer's disease and hypoplastic left heart syndrome positions it favorably in the biotechnology market.
- 首席执行官 Wa'el Hashad 已安排在生物技术展示会上发表演讲，这表明了与生物技术社区的积极互动以及潜在的投资者兴趣。
- 该公司的主要研发产品 Lomecel-b 已获得多个重要的 FDA 认证，展示了对其在关键领域发展所获得的监管认可和支持。
- Longeveron 专注于解决阿尔茨海默病和左心发育不良综合征等重大疾病的未满足医疗需求，使其在生物技术市场中处于有利地位。
Potential Negatives
潜在负面因素
- Announcement of a presentation at an upcoming conference may imply the company is actively seeking investor interest, highlighting its need for additional capital or support at this clinical stage.
- The focus on multiple indications and the extensive FDA designations may also suggest a lack of definitive results or approvals thus far, raising concerns about the viability and progress of its lead therapy, Lomecel-B.
- Being classified as a clinical-stage biotechnology company emphasizes the high risks associated with its development pipeline, as tangible revenue-generating products are not yet available.
- 即将在即将举行的会议上宣布演讲可能意味着公司正在积极寻求投资者的兴趣，强调其在这一临床阶段对额外资本或支持的需求。
- 对多种适应症和广泛的FDA认证的关注也可能表明到目前为止缺乏明确的结果或批准，从而引发对其主要治疗方案Lomecel-b的可行性和进展的担忧。
- 被归类为临床阶段的生物技术公司强调了其开发管道所伴随的高风险，因为尚未有可产生实际营业收入的产品。
FAQ
常见问题
What is Longeveron Inc. known for?
Longeveron Inc.以什么而闻名？
Longeveron Inc. is a clinical stage biotechnology company developing cellular therapies for chronic and life-threatening aging-related conditions.
Longeveron Inc.是一家临床阶段的生物技术公司，正在开发用于治疗慢性及危及生命的与老龄化相关的疾病的细胞疗法。
When will Longeveron present at the Biotech Showcase?
Longeveron将在生物技术展示会上何时进行演讲？
Longeveron will present on January 14, 2025, from 4:00 to 4:30 p.m. PT.
Longeveron将在2025年1月14日下午4:0万亿至4:30进行演讲。
How can I access the Longeveron presentation webcast?
我怎样才能访问Longeveron的演示网络直播？
The webcast can be accessed in the "Events and Presentations" section of the Company's website.
可以在公司网站的“活动与演示”部分访问网络直播。
What is Lomecel-B?
Lomecel-B是什么？
Lomecel-B is an investigational MSC therapy product developed by Longeveron, targeting a range of chronic conditions.
Lomecel-b是一种正在研究中的MSC疗法产品，由Longeveron开发，针对一系列慢性疾病。
What FDA designations has Longeveron received?
Longeveron获得了哪些FDA认定？
Longeveron has received Orphan Drug, Fast Track, Rare Pediatric Disease, and RMAT designations for its programs.
Longeveron已获得孤儿药、快速通道、罕见儿科疾病和RMAt认定的项目。
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
免责声明：这是由GlobeNewswire分发的新闻稿的人工智能生成摘要。用于总结这份稿件的模型可能会出错。请在这里查看完整发布。
$LGVN Insider Trading Activity
$LGVN内部交易活动
$LGVN insiders have traded $LGVN stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
$LGVN内部人士在过去6个月的公开市场上交易过$LGVN股票1次。在这些交易中，有0次是购买，1次是出售。
Here's a breakdown of recent trading of $LGVN stock by insiders over the last 6 months:
以下是过去6个月内部人士对$LGVN股票的近期交易情况：
- KHOSO BALUCH sold 1,250 shares.
- KHOSO BALUCH 出售了1,250股。
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
要跟踪内部交易，请查看Quiver Quantitative的内部交易特斯拉-仪表。
$LGVN Hedge Fund Activity
$LGVN对冲基金活动
We have seen 11 institutional investors add shares of $LGVN stock to their portfolio, and 10 decrease their positions in their most recent quarter.
我们看到11家机构投资者在最近一个季度增加了$LGVN股票的持有量，10家在最近一个季度减少了他们的持仓。
Here are some of the largest recent moves:
以下是最近的一些重大变动：
- RENAISSANCE TECHNOLOGIES LLC removed 146,700 shares (-100.0%) from their portfolio in Q3 2024
- GEODE CAPITAL MANAGEMENT, LLC added 97,953 shares (+316.0%) to their portfolio in Q3 2024
- TWO SIGMA INVESTMENTS, LP removed 46,041 shares (-100.0%) from their portfolio in Q3 2024
- VANGUARD GROUP INC added 44,984 shares (+inf%) to their portfolio in Q3 2024
- CITADEL ADVISORS LLC removed 22,485 shares (-100.0%) from their portfolio in Q3 2024
- SQUAREPOINT OPS LLC removed 17,831 shares (-100.0%) from their portfolio in Q3 2024
- STATE STREET CORP added 15,180 shares (+inf%) to their portfolio in Q3 2024
- RENAISSANCE TECHNOLOGIES LLC在2024年第三季度从其投资组合中移除了146,700股（-100.0%）。
- GEODE CAPITAL MANAGEMENT, LLC在2024年第三季度增加了97,953股（+316.0%）到他们的投资组合中
- TWO SIGMA INVESTMENTS, LP在2024年第三季度从他们的投资组合中移除了46,041股（-100.0%）
- VANGUARD GROUP INC在2024年第三季度增加了44,984股（+inf%）到他们的投资组合中
- CITADEL ADVISORS LLC在2024年第三季度从他们的投资组合中移除了22,485股（-100.0%）
- SQUAREPOINT OPS LLC在2024年第三季度从他们的投资组合中移除了17,831股（-100.0%）
- STATE STREET CORP在2024年第三季度增加了15,180股（+inf%）到他们的投资组合中
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
要跟踪对冲基金的股票投资组合，请查看Quiver Quantitative的机构持有情况仪表。
Full Release
完整发布
MIAMI, Dec. 18, 2024 (GLOBE NEWSWIRE) --
Longeveron Inc.
(NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Wa'el Hashad, Chief Executive Officer, will give a corporate presentation at Biotech Showcase, being held January 13-15, 2025.
迈阿密，2024年12月18日（环球新闻通讯） --
隆杰公司
(纳斯达克：LGVN)，是一家临床阶段再生医疗生物技术公司，正在开发用于生命威胁和与衰老相关的慢性病症的细胞疗法，今天宣布首席执行官Wa'el Hashad将在2025年1月13日至15日举行的生物技术展示会上进行企业演讲。
Details for the Company's presentation:
公司演讲的详情：
|
Date: |
Tuesday, January 14, 2025 |
|
Time: |
4:00 – 4:30 p.m. PT |
|
日期： |
2025年1月14日，星期二 |
|
时间： |
太平洋时间下午4:00 – 4:30 |
The webcast for this conference presentation may be accessed at the "
Events and Presentations
" section of the Company's website. A replay of the webcast will be available on the Longeveron website following the conference.
本次会议演讲的网络直播可在“
活动与演示
”部分的公司网站上进行访问。会议后，Longeveron网站将提供网络直播的回放。
About Longeveron Inc.
关于Longeveron公司
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company's lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease (AD), and Aging-related Frailty. Lomecel-B development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit
or follow Longeveron on
LinkedIn
,
X
, and
Instagram
.
Longeveron是一家临床阶段的生物技术公司，致力于开发再生药物以满足未满足的医疗需求。公司的主要研发产品是Lomecel-b，这是一种从年轻健康成人捐献者的骨髓中分离出的同种异体医学信号电芯（MSC）治疗产品。Lomecel-b具有多种潜在的作用机制，包括促血管、促再生、抗炎和组织修复和愈合效果，在各种疾病领域具有广泛的潜在应用。Longeveron目前正追求三个管道适应症：缩小型左心综合症（HLHS）、阿尔茨海默病（AD）和与衰老相关的虚弱。Lomecel-b开发项目已获得五项显著而重要的FDA认定：对于HLHS项目 - 孤儿药认定、快速通道认定和稀有儿科疾病认定；对于AD项目 - 再生医学先进疗法（RMAT）认定和快速通道认定。有关更多信息，请访问
或关注Longeveron的社交媒体
LinkedIn
,
X
，和
Instagram
.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
投资者及媒体联系：
德里克·科尔
投资者关系顾问方案
derek.cole@iradvisory.com